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ABSTRACT Over the last two decades, antimicrobial resistance has become a global
health problem. In Gram-negative bacteria, metallo-b-lactamases (MBLs), which inacti-
vate virtually all b-lactams, increasingly contribute to this phenomenon. The aim of this
study is to characterize VIM-52, a His224Arg variant of VIM-1, identified in a Klebsiella
pneumoniae clinical isolate. VIM-52 conferred lower MICs to cefepime and ceftazidime
compared to VIM-1. These results were confirmed by steady-state kinetic measurements,
where VIM-52 yielded a lower activity toward ceftazidime and cefepime but not against
carbapenems. Residue 224 is part of the L10 loop (residues 221 to 241), which borders
the active site. As Arg 224 and Ser 228 both play an important and interrelated role in
enzymatic activity, stability, and substrate specificity for the MBLs, targeted mutagenesis
at both positions was performed and further confirmed their crucial role for substrate
specificity.
KEYWORDS antibiotic resistance, metallo-b-lactamase, Klebsiella pneumoniae,
biochemical characterization, carbapenemase, MBL, metalloenzymes
Multidrug-resistance in Gram-negative bacteria represents a major public healthproblem (1). The emergence and spread of acquired carbapenemases such as
metallo-b-lactamases (MBLs) are of particular concern (2). MBLs were first reported in
1966, and were not initially considered a serious threat for antimicrobial chemother-
apy, as they were mostly chromosomally encoded in nonpathogenic bacteria (3). The
situation is now different, as the genes encoding MBLs are frequently located on mo-
bile genetic structures, facilitating dissemination and spread among clinically relevant
Gram-negative bacteria (4, 5). The MBLs are divided into three subclasses, B1, B2, and
B3. The most important acquired MBLs are members of subclass B1, including Verona
integron-encoded metallo-b-lactamase (VIM) (6) and New Delhi metallo-b-lactamase
(NDM) (7). BlaVIM-1 was first identified as a chromosomally encoded within a class I inte-
gron in a Pseudomonas aeruginosa clinical isolate (6). Today, VIM-1-like enzymes are
mostly identified in multidrug-resistant Enterobacterales species (4, 5). The VIM enzyme
family currently includes 73 different variants (http://www.bldb.eu/) (8) divided into 5
different clusters of closely sequence-related enzymes, namely, VIM-1 and VIM-2 (the 2
major clusters) and then VIM-7, VIM-12, and VIM-13 variants (9). Similar to other MBLs,
VIM enzymes hydrolyze all b-lactams with the exception of monobactams. Their fold
forms an abba sandwich and their active site is located in a central groove on one
edge of the two b sheets. The active site is able to bind two zinc ions, positioned,
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respectively, in the tetrahedral Zn1 site (formed by the conserved H116, 118, and 196)
and the Zn2 site, which includes D120, C221, and H263 (BBL numbering scheme) (10–
14). Amino acids at position 224 and 228 are part of the L10 loop (residues 221 to 241)
located near the active site. Compared to the other subclass B1 MBLs (NDM-1 and IMP-
1), which harbor a positively charged lysine at position 224, VIM enzymes all display
amino acids at position 224 which abolish the presence of a positive charge near the
active site (histidine for VIM-1 variants, tyrosine for VIM-2 variants, but leucine 224 for
VIM-26 and VIM-28). This affects the interaction of VIM enzymes with the conserved
carboxylic function of the b-lactam compounds and its intrinsic stability (15, 16). The
presence of an arginine at position 228 can structurally replace the function of the Lys
224 (17), but most of the variants containing an Arg 228, such as VIM-4, display a lower
hydrolysis efficiency against expanded-spectrum cephalosporins. Within the VIM-1 sub-
group, the presence of a serine at position 228 increases the accessibility of the active
site and its activity toward substrates with bulky side chains in C3-like the third and/or
fourth generation cephalosporins. We report here the characterization of a VIM-52-pro-
ducing K. pneumoniae clinical isolate (Kp_20150593) and the kinetic parameters of the
purified VIM-52 protein. VIM-52 differed from VIM-1 by a single histidine-to-arginine
substitution at position 224. Due to the importance of the residue at positions 224 and
228, we generated different mutants of VIM-1 (H224A, H224D, and H224K) and VIM-52
(S228A, S228D, S228K, and S228R) to explore their influence on the structure of the
L10 loop, the active site, and the VIM substrate specificity. The rationale behind these
choices was to replace the existing amino acids by a small neutral amino acid (alanine),
a positively charged amino acid (lysine), and a negatively charged amino acid (aspar-
tate). In addition, for VIM-52, we further replaced the S228 (a polar amino acid) by the
positively charged R in order to explore the effect of the potential steric and charge
hindrance of the 2 arginines at positions 224 and 228. Three dimensional modeling
and molecular dynamics simulation were also performed.
RESULTS
VIM-52, a single amino acid variant of VIM-1: clinical context and molecular
identification. A 67-year-old Belgian patient developed a severe acute respiratory dis-
tress episode during a holiday stay in Greece and was hospitalized in a local intensive
care unit (ICU), requiring intubation and mechanical ventilation. Three days later, he
was repatriated to the ICU of a general hospital in Belgium, where microbiological sam-
ples collected from several anatomical sites (sputum, rectal swab, and urine) cultured a
carbapenem-resistant K. pneumoniae isolate (Kp_20150593). The isolate displayed
high-level resistance to penicillins, third-generation cephalosporins and carbapenems,
but remained susceptible to cefepime and to aztreonam (Table 1).
In-house multiplex PCR confirmed the presence of a blaVIM gene and subsequent
Sanger sequencing revealed a blaVIM-52 allele, a novel single amino acid variant H224R
of VIM-1 (Fig. 1A).
Whole-genome sequencing (WGS) of the VIM-52-producing Kp_20150593 isolate
revealed that Kp_20150593 belonged to the sequence type (ST) 147 and capsular type
was KL64. VIM-1-producing K. pneumoniae ST147 isolates have been reported previ-
ously in several hospitals in Greece (18), and K. pneumoniae ST147 is considered as an
emerging high-risk clone harboring different carbapenemases and responsible for hos-
pital outbreaks all over Europe (19, 20). To the best of our knowledge, no other case of
a VIM-52-producing isolate has been reported.
The blaVIM-52 gene is located on a 5,884-bp contig presenting a BLAST best hit (query
cover 100%, E value 0.0, percentage identity 99.97%) with a region of the plasmid
pIncRIncN from K. pneumoniae strain 1_GR_13 (CP027047.1), which harbors a blaVIM-27
gene (data not shown). The blaVIM-52 gene is embedded in a class I integron together
with two additional gene cassettes conferring resistance to aminoglycoside, (aac(69)-I
and aph(399)-Ia, and one to trimethoprim, dfrA1 (Fig. 1B). The blaVIM-52 gene cassette is
inserted at the first position of the variable region of the integron, immediately down-
stream to the integron-borne strong promoter Pc (Fig. 1B).
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An ;50-kb plasmid was extracted from Kp_20150593 by the Kieser method. This
plasmid was electroporated to Escherichia coli strain Top10 and a mating-out experiment
using J53 azide-resistant E. coli as the recipient strain confirmed that pIncRIncN-VIM-52 is
a self-conjugative plasmid. The transconjugant and the transformant displayed a similar
antimicrobial resistance profile, which was different from the parental Kp_20150593 iso-
late (Table 1), indicating that resistance to ciprofloxacin, colistin, and fosfomycin are not
related to the VIM-52 plasmid. The mechanisms of resistance to these antibiotics will not
be investigated in the present study.
Site-directed mutagenesis of H224 and S228 amino acids in VIM-1 and VIM-52,
respectively. The MICs of E. coli producing VIM-1 and variants against different beta-lactam
antibiotics (Fig. 2) were determined by broth microdilution (Table 2). Compared to VIM-1,
the natural H224R substitution in VIM-52 conferred a very similar resistance profile to carba-
penems and most b-lactams (no more than 1 dilution difference, Table 2). Nevertheless, for
ceftazidime, a difference of at least two dilutions was detected (.128 to 64mg/ml for VIM-1
and VIM-52, respectively). For cefepime, a dramatic drop of MIC value was observed (from
64 to 0.25mg/ml), suggesting an almost complete loss of cefepime hydrolysis by VIM-52.
In other VIM-1 variants at position 224, such as H224D, an increase in the susceptibil-
ity to ertapenem was observed (0.25 mg/ml instead of 1 mg/ml for VIM-1), while the
mutation H224K increased the susceptibility to meropenem (1mg/ml instead of 4 mg/ml
for VIM-1). Nevertheless, the most dramatic effect was observed with cefepime (Table 2),
for which the resistance profile ranged from 64 mg/ml for VIM-1 to 0.25 mg/ml for VIM-
52 with a gradual increase of the susceptibility according to the nature of the mutation
at position 224 (MIC of VIM-1. H224A. H224D. H224K. H224R [VIM-52]).
Mutations performed on VIM-52 at position 228, such as S228A and S228K, had
minor effects on MIC values, while S228R led to an additional decreased resistance to
meropenem compared to VIM-52. On the contrary, S228D mutations restored a partial
resistance phenotype to cefepime (2 mg/ml), while susceptibility to ertapenem was
increased (0.25 mg/ml) (Table 2).
Four representative mutants (VIM-1 H224K; VIM-52 [H224R], VIM-52 S228D, and
S228R) were further studied by molecular modeling and purified to homogeneity in
order to determine their hydrolytic parameters.
TABLE 1MIC (mg/ml) values evaluated by broth microdilution of K. pneumoniae 20150593












Temocillin .128 16 .128 16 .128
Ticarcillin .512 8 .512 8 .512
Ticarcillin/clavulanic acida .256 8 .256 4 .256
Piperacillin-tazobactamb .256 2 .256 2 256
Cefepime 2 ,0.12 0.25 ,0.12 0.5
Cefotaxime .128 ,0.12 .128 0.25 128
Ceftazidime 64 0.5 64 1 32
Ceftazidime-avibactamc .32 0.25 32 0.25 8
Ceftolozane-tazobactamb .32 0.5 .32 0.5 .32
Ertapenem 16 ,0.06 2 ,0.06 1
Imipenem 32 0.25 4 0.5 2
Meropenem 16 ,0.06 2 ,0.06 1
Aztreonam 0.25 ,0.12 0.5 ,0.12 0.5
Gentamicin 1 ,0.5 1 ,0.5 2
Tobramycin 8 ,0.5 8 ,0.5 16
Amikacin 16 ,1 16 4 16
Ciprofloxacin .16 ,0.06 ,0.06 ,0.06 ,0.06
Fosfomycin 64 ,4 ,4 ,4 ,4
Tigecycline 0.5 0.25 0.12 0.25 0.25
Colistin .64 0.5 0.5 1 1
aClavulanic acid used at 2mg/ml.
bTazobactam used at 4mg/ml.
cAvibactam used at 4mg/ml.
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Structural analysis of the VIM variants. A three-dimensional model was con-
structed for each of these VIM variants, starting from the crystal structure of VIM-1
(PDB code 5N5I) (16), then submitted to molecular dynamics (MD) simulations, which
very quickly reached an equilibrium, with root-mean-square deviation (RMSD) values
of about 1 Å that were conserved throughout (Fig. S1 in the supplemental material).
Each mutant features a specific conformation of loop L10 (residues 221 to 241) (Fig. S2)
and a specific shape for the binding site (Fig. 3). The hydrogen bond interactions that
are controlling the conformation of loop L10 are presented in Fig. 4. The hydrogen
bonds between the side chain of T275 and the backbone of the residues in position
224, as well as between the side chain of H274 and the backbone of the residue in
position 228, are present in all six VIM variants studied, with the exception of K224/
S228 (Fig. 4b), where H274 is absent. Additional hydrogen bonds were observed in
these mutants, all of them constituting essential elements to define the conformation
of the L10 loop (Fig. 4).
Steady-state kinetic analysis. Table 3 shows that VIM-52 displayed higher catalytic
efficiencies (kcat/Km) toward benzylpenicillin and cefotaxime compared to VIM-1, but
lower toward ceftazidime and cefepime and similar toward imipenem and meropenem.
Also, kcat values for meropenem and ertapenem (0.3 s21) were lower than the kcat for imi-
penem (2.2 s21). This suggests that the active site of VIM-52, because of the presence of
the large positively charged R224, is less able to interact with bulky and/or positively
charged C3 substrates (Fig. 2). Indeed, cephalothin and cefotaxime, which possess
the same small, uncharged C3 acetoxymethyl group substituent, are hydrolyzed with
the same efficiency (Table 3), despite that cefotaxime possesses a larger C7-lateral chain
FIG 1 VIM-52 sequence analysis and blaVIM-52 locus characterization. (A) Multiple alignment of VIM-1 (UniProtKB Q5GN09), VIM-2 (UniProtKB Q9K2N0), VIM-4
(UniProtKB Q8KRJ3), and VIM-52 (this study). Amino acids positions are numbered according to the BBL scheme. Positions 224 and 228 are framed. “Z”
indicates the residues interacting with Zn. (B) Class I integron annotation. The 59CS includes intl gene, while the 39CS includes the qacED1, sul1, and orf5
genes. The gene cassettes comprise the following genes: blaVIM-52 (in purple), aac(69)-I, dfrA1, and aph(399)-Ia. Gene expression is under the control of a Pc
strong (PcS) promoter and a P2 promoter. AttC and attL sites are depicted in green and in light green, respectively.
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(2-[2-amino-1,3-thiazol-4-yl]-2-[methoxyimino] acetyl) amino group instead of the 2-thie-
nylacetyl nitrilo group for cephalothin. Interestingly, the only structural difference
between cefepime and cefotaxime is the presence of a bulky and positively charged C3
lateral chain (1-methylpyrrolidinium-1-methyl group) in cefepime, instead of the small
acetoxymethyl group for cefotaxime (Fig. 2). The presence of this group results in a
reduced affinity (increase in Km value) for cefepime compared to cefotaxime and thus a
large reduction of the VIM-52 catalytic efficiency. The same observation can be made
with ceftazidime, which also presents a bulky and positively charged C3 substituent (N-
methyl-pyridinium group). For these b-lactams, we noted a more than 10-fold increase
in the Km values compared to cephalothin or cefotaxime. Therefore, we were not able to
FIG 2 Chemical structures of the b-lactam antibiotics used in this study.
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measure kcat and Km independently since, in our experimental conditions, their hydrolysis
was characterized by a first-order kinetic. Molecular docking calculations of cefotaxime
with the R224/S228 variant provided a possible explanation for these results, showing a
binding mode with hydrogen bonds of the side chain of R224 with the carboxylate
TABLE 2MIC (mg/ml) evaluated by broth microdilution of E. coli Top 10 pTOPO-VIM-1, pTOPO-VIM-52, and their respective mutants
MBLs pTOPO plasmid
Penicillins Cephalosporins Carbapenems Monobactam
PTZa TEM TIC TCC FEP CTX CAZ CZA C/T ERT IMP MER ATM
No MBL 2 16 8 8 #0.12 #0.12 0.5 0.5 0.5 #0.06 0.125 #0.06 0.125
VIM-1 .256 .128 .512 .256 64 128 .128 .32 .32 1 8 4 0.25
VIM-1 H224A .256 .128 .512 .256 16b .128 .128 .32 .32 0.5 8 2 #0.12
VIM-1 H224D 128 128 .512 .256 8 64 128 .32 .32 0.25 4 2 0.25
VIM-1 H224K 128 .128 .512 .256 0.5 64 128 .32 .32 1 4 1 0.25
VIM-52 .256 .128 .512 .256 0.25 128 64 32 .32 1 4 2 0.25
VIM-52 S228A 256 .128 .512 .256 0.25 128 32 32 .32 0.5 4 1 #0.12
VIM-52 S228D 256 .128 .512 .256 2 64 128 .32 .32 0.25 4 1 0.25
VIM-52 S228K 256 .128 .512 .256 #0.12 64 32 32 .32 1 4 1 #0.12
VIM-52 S228R 128 .128 .512 .256 #0.12 64 16 8 .32 1 4 0.5 0.25
aPTZ, piperacillin-tazobactam (4mg/ml); TEM, temocilin; TIC, ticarcillin; TCC, ticarcillin-clavulanate; FEP, cefepime; CTX, cefotaxime; CAZ, ceftazidime; CZA, ceftazidime-
avibactam; C/T, ceftolozane-tazobactam; ERT, ertapenem; IMP, imipenem; MER, meropenem; ATM, aztreonam.
bImportant changes are highlighted in boldface type.
FIG 3 Binding site shape variability of the six VIM variants revealed by molecular dynamic simulations. The
proteins are represented as surfaces colored in orange (a, H224/S228), cyan (b, K224/S228), brown (c, R224/D228),
light green (d, R224/R228), purple (e, R224/S228), and gray (f, Y224/R228). The zinc ions and the stabilized water
molecules predicted by HOP are represented as mauve and red spheres, respectively.
de Barsy et al. Antimicrobial Agents and Chemotherapy













































group and with the carbonyl oxygen of the ester group of cefotaxime (Fig. 5a). The bind-
ing modes of cefepime (Fig. 5b) or ceftazidime are slightly different due to repulsive
interactions between the side chain of R224 and the positively charged substituents in
position C3, thus explaining the higher Km values determined experimentally for these
two molecules. With its small and neutral substituent in C3, cephalothin remains a good
substrate for both VIM-1 and VIM-52 MBLs.
VIM-52 and VIM-1 displayed a similar catalytic efficiency (kcat/Km) toward carbape-
nems. Nevertheless, kcat and Km for meropenem were strongly reduced compared to
VIM-1. These results suggested different modes of interaction of meropenem with the
active site residues. Molecular docking calculations on the R224/R228 variant showed
strong hydrogen bonds between the carboxylate group of meropenem and the side
chain of R224 in VIM-52, which are not possible with the shorter side chain of H224 in
VIM-1 (Fig. 6a). A similar explanation was found for benzylpenicillin, which is a better
substrate for VIM-52 (Fig. 6b). If we compare the enzyme activities toward third and
fourth generation cephalosporins, we can note that cefotaxime was a better substrate
for VIM-52 (kcat/Km for VIM-52 is 5 times higher). In contrast, VIM-52 was less active
against cefepime and ceftazidime than VIM-1, with a ratio of kcat/Km for VIM-52 and
VIM-1 of 0.026 and 0.15, respectively. These latter observations are in agreement with
the MICs determined for E. coli TOP10 producing VIM-1 or VIM-52 (Table 2). This con-
firmed that the presence of an arginine in position 224 is less favorable to accommo-
date the positively charged C3-N-methyl pyrrolidine group of the cephems (Fig. 5).
Furthermore, the H224K VIM-1 variant showed about 100-fold reduced activity toward
FIG 4 Stabilizing interactions in the loop 221 to 241 of the six VIM variants. The proteins are colored
in orange (a, H224/S228), cyan (b, K224/S228), brown (c, R224/D228), light green (d, R224/R228),
purple (e, R224/S228), and gray (f, Y224/R228). The zinc ions are represented as mauve spheres and
the hydrogen bonds as black strings.
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cefepime (ratio of kcat/Km for the H224K VIM-1 variant versus VIM-1 was 0.007).
Interestingly, the H224K VIM-1 mutant was more active against benzylpenicillin,
cefotaxime, imipenem, and meropenem (ratios of 123, 8, 7.7, and 30, respectively)
(Table 3). The presence of a lysine at position 224 enhances the catalytic efficiency to-
ward carbapenems and benzylpenicillin but does not explain MICs against carbape-
nems (Table 2). This discrepancy might suggest a lower level of expression and/or sta-
bility of this mutant, which is supported by the Western blot experiments showing a
lower signal for VIM-1 H224K mutant than for VIM-1 (Fig. S3). This experimental obser-
vation might explain why H224K has never been identified despite being more active
against carbapenems than H224R (i.e., VIM-52).
We also explored the function of the amino acid 228 in VIM-52. Our data showed that
the S228D VIM-52 mutant was more or equally efficient against all the tested substrates
compared to the unmutated VIM-52 (Table 4; R4-VIM-52 ratio). This phenomenon was
mainly due to the increase of the kcat values. Interestingly, the catalytic efficiency of VIM-
52 S228R against ceftazidime and cefepime dropped compared to VIM-52, mainly due to
the lower kcat of the mutant. On the other hand, activity against carbapenems of this mu-
tant rose due to higher kcat for imipenem (20 s21 instead of 2.2 s21 for VIM-52) and a
decrease of Km for meropenem (0.03 mM instead of 0.7 mM for VIM-52) and ertapenem
(0.06 mM instead of 0.5 mM for VIM-52), with the kcat remaining roughly unchanged
(Table 4). The analysis of the enzymatic profile of the double R224 R228 mutant com-
pared to VIM-1 showed a major drop in activity against ceftazidime and cefepime due to
the decrease of the kcat value and a higher catalytic efficiency against cefotaxime and
carbapenems.
DISCUSSION
As MBLs are increasingly spreading in Gram-negative bacteria, novel variants of
known MBLs with altered substrate specificities will be discovered. Here, we have char-
acterized VIM-52, a novel H224R VIM-1 variant present in a clinical isolate of K. pneumo-
niae belonging to ST147, both phenotypically and biochemically. The blaVIM-52 gene
FIG 6 Molecular determinants for the selectivity of meropenem and benzylpenicillin on specific VIM variants.
The docking complex of meropenem (a, dark green) and benzylpenicillin (b, magenta) with the R224/R228
variant of VIM (colored in light green) is superposed with the H224/S228 variant (colored in orange). The zinc
ions are represented as mauve spheres and the hydrogen bonds as black strings.
FIG 5 Molecular determinants for the selectivity of cefotaxime and cefepime on specific VIM variants. Docking
complexes of cefotaxime (a, magenta) and cefepime (b, cyan) with the R224/S228 variant of VIM (colored in
light green). The zinc ions are represented as mauve spheres and the hydrogen bonds as black strings.
VIM-52 Characterization Antimicrobial Agents and Chemotherapy













































was embedded in a class I integron carried by a 50-kb IncR-IncF plasmid, whose
sequence is highly similar to a plasmid sequence (accession number NZ_CP027047.1)
found in a K. pneumoniae strain 1_GR_13, also belonging to ST147 (21) and isolated
from a Greek patient in 2013. Thus, it is likely that the patient acquired Kp_20150593
during his hospital stay in Greece.
Constitutive expression of the blaVIM-52 gene in E. coli strain TOP10 suggested that
VIM-52 is a carbapenemase with impaired cefepime hydrolysis (MIC = 0.25 mg/ml)
compared to VIM-1 (MIC = 64 mg/ml). Steady-state kinetic parameters confirmed the
phenotypical observation and revealed VIM-52 to have a nearly 40-fold lower activity
against cefepime compared to VIM-1. These results are in line with a recent publication
that compared the MIC values of VIM-1 and VIM-52 (22). While this group observed
that the H224R mutation had no or poor effect on the level of carbapenem resistance,
they noticed a significant drop in MICs for ceftazidime (4-fold), similar to what we
observed, but they did not test cefepime.
Amino acids at position 224 and 228 are known to be important for substrate bind-
ing (17). In order to further explore the amino acid specificities at these positions, we
prepared several point mutant derivatives by directed mutagenesis. We were able to
show that the presence of an arginine at position 228 affects the substrate profile, i.e.,
an increased catalytic efficiency against imipenem and meropenem and a decreased
catalytic efficiency against cefepime and ceftazidime (Table 4). This is in agreement
with the activity profile of VIM-13 and VIM-19, respectively (23, 24).
In many subclass B1 (5, 25) and B2 (12) MBLs, the conserved Lys residue at position
224, close to the active site, plays an important role in substrate binding (17). In
the case of VIM enzymes, K224 is substituted by H224 in VIM-1 and by Y224 in VIM-2.
The shorter side chain of histidine and the uncharged lateral chain of tyrosine prevent
the interaction of these two amino acids with the carboxylate moiety (C4 or C3) of the
substrate. The presence of K224 allows the interaction with the substrate but also cre-
ates a stronger interaction with a- carbonyl moiety of the main chain of A231 and the
water molecule shared with H196. This mutation favors a better docking of the antibi-
otic in the active site pocket and the polarization of the water molecule may increase
the acid Lewis strength of the Zn2 and its hydrolytic activity (26). On the other hand,
the presence of K224 resulted in a decrease of the kcat value and an increase of the Km
value for cefepime, which resulted in a sharp decrease of the catalytic efficiency com-
pared to VIM-1 (R2 ratio for cefepime = 0.007) (Table 3). We noticed that the catalytic
efficiency of this VIM-1 H224K mutant is enhanced for cefotaxime (R2 ratio for cefotax-
ime = 8). Knowing that the only difference between cefotaxime and cefepime structure
is the nature of the C3 lateral chain, our hypothesis is that the presence of a bulky and
positively charged C3 lateral chain of cefepime affects its positioning in the active site
and therefore its hydrolysis by the MBL.
TABLE 4 Steady-state kinetic parameters for the VIM-52 mutants S228D and S228R
Antibiotic(s)
VIM52-S228D VIM52-S228R
kcat (s21) Km (mM) kcat /Km (mM21 s21) R4a R5b kcat (s21) Km (mM) kcat /Km (mM21 s21) R6c R7d R8e
Benzylpenicillin 8406 60 846 4 106 2 3.9 294 3206 20 166 2 206 4 7.7 590 5
Cephalothin 3506 50 306 4 116 3 2 2 5006 70 256 3 206 3 3.6 4 1.8
Ceftazidime .20 .280 0.076 0.01 5.8 1 .2.5 .550 0.0056 0.001 0.4 0.06 11
Cefepime .30 .300 0.16 0.01 1 0.03 .1.5 .320 0.0056 0.002 0.05 0.001 0.05
Cefotaxime 2706 10 656 8 46 0.6 1.2 6 4506 60 506 5 96 2 2.7 13 1.6
Imipenem 2.56 0.4 0.36 0.05 86 2.5 4.4 6 206 1 16 0.2 206 5 11 15 11
Meropenem 36 0.2 1.56 0.3 26 0.5 4.4 7.4 0.26 0.04 0.036 0.01 6.66 3 15 25 2.7
Ertapenem 1.86 0.3 2.86 0.4 0.66 0.2 1 ND 0.66 0.1 0.066 0.01 106 3 16 ND 500
aR4, ratio kcat/Km VIM-52 S228D to kcat/Km VIM-52. Boldface type indicates ratio values; ND, not done.
bR5, ratio kcat/Km VIM-52 S228D to kcat/Km VIM-1.
cR6, ratio kcat/Km VIM-52 S228R to kcat/Km VIM-52.
dR7, ratio kcat/Km VIM-52 S228R to kcat/Km VIM-1.
eR8, ratio kcat/Km VIM-52 S228R to kcat/Km VIM-2.
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It has been hypothesized that R228 (17) may act as stabilizer of carbapenems in the
catalytic pocket of the MBLs. This seems confirmed by the observation of the activity
enhancement against carbapenems of the VIM-52 S228R (from 11- to 460-fold com-
pared to VIM-52, VIM-1, or VIM-2). On the contrary, we confirmed that the substitution
of S228 with arginine dramatically lowered the activity against ceftazidime and cefe-
pime, while not against cefotaxime. Our data underline the importance of the large
positively charged C3, especially when positions 224 and 228 are both positively
charged (R). The presence of the lateral chain of arginine induced steric clashes and
hindrance, compromising the hydrolysis of cefepime and ceftazidime.
Interestingly, with the mutation H224K VIM-1 (S228), we also observed an increased
catalytic efficiency against imipenem and meropenem and a decreased catalytic effi-
ciency against cefepime and ceftazidime as in S228R VIM-52. This further suggests that
R228 could replace the K224 for substrate binding and confirmed the importance of
residues 224 and 228 for the carbapenemase activity in MBL (13, 14, 25).
MATERIALS ANDMETHODS
Antibiotics. Kanamycin was purchased from MP Biomedicals, France. Chloramphenicol, benzylpeni-
cillin, cephalotin, cefotaxime, and ceftazidime were purchased from Sigma-Aldrich, (Overijse, Belgium).
Cefepime was a gift from Fresenius Kabi, (Schelle, Belgium). Imipenem and ertapenem were purchased
from MSD, (Brussels, Belgium) and meropenem from AstraZeneca (Dilbeek, Belgium).
Bacterial isolates. The clinical strain Kp_20150593 expressing the VIM-52-ß-lactamase was used for
cloning of the blaVIM-52 gene. E. coli TOP10 (Invitrogen, Saint-Aubin, France) and Stellar E. coli competent
cells (Invitrogen, Merelbeke, Belgium) were used for cloning, azide-resistant E. coli strain J53 for conjuga-
tion experiments, and E. coli strain Rosetta (DE3) (Novagen, Fontenay-sous-Bois, France) for overexpres-
sion experiments.
Bacterial identification, antimicrobial susceptibility testing, and carbapenemase detection.
Bacterial identification to the species level was performed using matrix-assisted laser desorption–time of
flight (MALDI-TOF) mass spectrometry (MALDI Biotyper; Bruker Daltonics, Bremen, Germany).
Antimicrobial susceptibility testing was determined by disc diffusion on Mueller-Hinton agar plates
(Bio-Rad, Marnes-La-Coquette, France) according to the CLSI guidelines (CLSI M-100-S15). MIC values
were determined by broth microdilution using Sensititre plates (Trek Diagnostic Systems, Cleveland, OH,
USA).
Carbapenemase activity was assessed by biochemical (Rapidec, bioMérieux, Marcy-l-Etoile, France)
and electrochemical BYG Carba tests (27). The carbapenemase gene was detected by an in-house PCR
ISO15189 certified. PCR products were subsequently Sanger sequenced by an external sequencing pro-
vider (Macrogen, Seoul, Korea) (28).
Plasmid analysis, conjugation, and transformation assays. Plasmid DNA was extracted from iso-
late Kp_20150593 by the Kieser method and analyzed by 0.7% agarose gel electrophoresis using as a
plasmid size marker the plasmid extract of the E. coli NCTC50192 strain, which harbors four plasmids of
154, 66, 48, and 7 kb. The plasmid extract of Kp_20150593 was used to transform E. coli TOP10 by elec-
troporation using the Gene Pulser II apparatus. Transformants were selected on LB agar plates contain-
ing 100 mg/ml of ampicillin. A solid mating experiment was performed using E. coli J53 (azide resistant)
as a recipient strain. The transconjugants were selected on LB agar plate containing 100 mg/ml of azide
and 100 mg/ml of ampicillin. Transformants and transconjugants were tested by disk diffusion and broth
microdilution antibiograms and colony PCR using primers targeting the blaVIM gene (29).
Whole-genome sequencing. Genomic DNA was extracted using NucliSENS easyMag (bioMérieux,
Marcy-l’Etoile, France), following the manufacturer’s instructions. A dual-indexed Illumina sequencing
library was constructed using Nextera DNA Flex library preparation (Illumina Inc, CA, USA). Libraries were
pooled and 100 pM was sequenced on the Illumina iSeq100 (2  150 bp). Sequence quality was
assessed by FastQC. Reads were trimmed using Trimmomatic. Genome assembly was performed using
Spades and assembly quality was assessed using Quast. Resistance genes and replicons were identified
using ResFinder (https://cge.cbs.dtu.dk/services/ResFinder/) and PlasmidFinder (https://cge.cbs.dtu.dk/
services/PlasmidFinder/), respectively. The contig number 38, harboring the blaVIM-52 gene (accession
number GenBank ANI25016.1), was annotated using RAST (https://rast.nmpdr.org/), Integrall (http://
integrall.bio.ua.pt/), and ISFinder (https://isfinder.biotoul.fr/blast.php). The contig number 38 sequence
was aligned against K. pneumoniae (TaxID 573) using the NCBI BLAST tool. Multilocus sequence type
(MLST) was determined using BIGSdb-Kp Pasteur database, while capsular type was determined using
Kaptive webtool (http://kaptive.holtlab.net/).
Site-directed mutagenesis, cloning, and expression. BlaVIM-1 and blaVIM-52 genes and their ribo-
some binding site (RBS) were amplified using Q5 High-Fidelity DNA polymerase (Bioké, Leiden, The
Netherlands) and ligated into the pCR-Blunt II-TOPO vector according to the manufacturer’s instructions
(Thermo Fisher, Brussels, Belgium). Ligation products were used to transform E. coli TOP10 by electropo-
ration and transformants were selected on LB containing 50 mg/ml kanamycin. Colonies were screened
by PCR using M13 forward (220) and M13 reverse universal primers. Amplified DNA were sequenced by
an external DNA sequencing service (Macrogen Inc., Seoul, South Korea) using the same primers to
check sequence and orientation of the inserted fragment.
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These two plasmids, pTOPO-VIM-1 and pTOPO-VIM-52, were used for PCR site-directed mutagenesis
using the QuikChange II site-directed mutagenesis kit according to the manufacturer’s recommenda-
tions (Agilent Technologies, Diegem, Belgium) to obtain the following variants: VIM-1 H224A, H224D,
and H224K; VIM-52 S228A, S228D, S228K, and S228R, after which they were ligated into the pCR-Blunt II-
TOPO plasmid. The MIC values of all the E. coli TOP10 strains constitutively expressing VIM-1 and VIM-52
and their mutants were determined by broth microdilution as described above.
Protein production and purification. BlaVIM-1 and blaVIM-52 genes and their variants were amplified
using Q5 High-Fidelity DNA polymerase and introduced into the pET26b plasmid using the In-Fusion HD
cloning kit (TaKaRa bio, Saint-Germain-en-Laye, France), following the manufacturer’s instructions. The
In-Fusion reaction mixtures were used to transform Stellar E. coli competent cells and transformants
were selected on LB containing 50 mg/ml kanamycin. Colonies were screened by PCR using T7 primers.
All the enzymes were produced in E. coli Rosetta (DE3) carrying pET26b/blaVIM-52, pET26b/blaVIM-1, and
mutants thereof. The cultures were performed in LB medium supplemented with kanamycin (50 mg/ml)
and chloramphenicol (30 mg/ml). The cultures were incubated overnight at 37°C under agitation and
40 ml was used to inoculated 1 liter of fresh LB medium supplemented as described above. IPTG (isopro-
pyl-b-D-thiogalactopyranoside; 50 mM final concentration) was added when the culture reached to an
optical density at 600 nm (OD600) of 0.7 and then the cultures were incubated overnight at 18°C. Cells
were harvested by centrifugation (5,000  g for 10 min at 4°C) and the pellets were resuspended in
40 ml of 50 mM MES buffer pH 6.5 with 50 mM ZnCl2 (buffer A). The bacteria were disrupted with the
help of a cell disrupter (Emulsiflex C3; Avestin GmbH, Germany), which allows cell lysis at a pressure of
5.500 kPa. The lysates were centrifuged at 45,000  g for 30 min. The cleared supernatants were recov-
ered and filtered through a 45-mm filter and were then loaded onto a Q Sepharose HP (GE Healthcare,
Machelen, Belgium) equilibrated with buffer A. The enzymes were eluted with a salt gradient using
buffer A and 50 mM MES, pH 6.5 with 1 M NaCl, (buffer B). The fractions containing b-lactamase activity
were pooled, and then dialyzed overnight in 25 mM HEPES, pH 7.5, 50mM ZnCl2, 1.2 M (NH4)2SO4. The di-
alysis sample was loaded onto Butyl Sepharose High Performance (20 ml) (Pharmacia Biotech) previously
equilibrated with 25 mM HEPES, pH 7.5, 50 mM ZnCl2, 1.2M (NH4)2SO4 (buffer A). The enzymes were
eluted with a salt-out gradient between buffer A and 25 mM HEPES, pH 7.5, 50 mM ZnCl2 (buffer B). The
active fractions were collected and concentrated on a YM-10 membrane (Amicon, Beverly, Mass.) to a
final volume of 2 ml. The sample was loaded in a molecular sieve Superdex 75 GL (10/300) column (GE
Healthcare, Belgium) equilibrated in 50 mM HEPES buffer pH 7.5, 50 mM ZnCl2 containing 0.2 M NaCl. At
the end of each purifications step, b-lactamase activity was routinely measured spectrophotometrically
by following the hydrolysis of a solution of 100 mM imipenem as previously described (14).
Steady-state kinetic parameters (Km and kcat) were determined by measuring substrate hydrolysis
under initial rate conditions and using the Hanes-Wolf linearization from the Michaelis-Menten equation
(30). Kinetic experiments were performed by following the hydrolysis of each substrate at 30°C in 25 mM
HEPES buffer pH 7.5, 50 mM ZnCl2 .The data were collected with a Specord 50 PLUS spectrophotometer
(Analytik, Jena, Germany). Each kinetic value is the mean of three different measurements.
Molecular modeling. Three-dimensional structures of mutants were generated using the swapaa
command implemented in UCSF CHIMERA (31), starting from the structure of VIM-1 (PDB code 5N5I)
(16).
Molecular dynamics simulations were performed with GROMACS version 4.6.5 (32) using the OPLS-
AA force field (33). The protein was centered in a cubic periodic box with at least 1.0 nm on each side.
The simulation box was then filled with TIP4P water molecules and the system neutralized with Na1 and
Cl– ions until reaching the physiological ionic strength (150 mM). Each system was energy-minimized
until convergence using a steepest descents algorithm. Molecular dynamics with position restraints on
backbone, with the exception of residues 223 to 232, which were unrestrained, was then performed for
50 ns. The Parrinello-Rahman method was used for pressure coupling (34) and the temperature was
coupled using the Nosé-Hoover method at 300 K (35, 36). Electrostatics were calculated with the parti-
cle-mesh Ewald method (37). The P-LINCS algorithm (38) was used to constrain bond lengths and a time
step of 2 fs was used throughout. All frames from each simulation were clustered and the most repre-
sentative conformations were used as input for molecular docking (see below). HOP software version
0.4.0 alpha2 (https://github.com/Becksteinlab/hop) (39) was used for water molecule dynamics analysis.
Molecular docking calculations were performed using the GOLD software (40) from the CCDC_2020 suite
and the GoldScore scoring function, with the representative conformers from molecular dynamics simu-
lations as receptors and the binding sites defined as a 20 Å radius around the Zn1 ion. All other parame-
ters had default values.
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